Caricamento quotazioni...
Previsioni
Non sono disponibili dati degli analisti per questa azienda.
Notizie Vai al feed delle notizie
Basel Medical Group appoints Neo Chun How Alton as interim CFO
The Basel Medical Group has appointed Neo Chun How Alton as interim CFO with effect from Monday. He succeeds Jianing Lu, who resigned as chief financial officer. Neo brings experience in corporate finance, restructuring, forensic accounting and tax policy, and was most recently deputy CEO of InCorp Global and worked as a part-time lecturer. » Altro su de.investing.com
Basel Medical Group remedies NASDAQ violation after filing amended 20-F
Basel Medical Group reports that the noncompliance with periodic reporting obligations was cured after filing the amended annual report on Form 20-F with the SEC on March 13, 2026, and that it meets NASDAQ rule 5250(c)(1). The stock rose nearly 16% last week to $0.69 but is down 83% year-to-date. The company reports more cash than debt, has a market capitalization of $12.96 million and operates clinical sites in Singapore. » Altro su de.investing.com
Dati finanziari dell'azienda
| (EUR) | dicembre 2025 | |
|---|---|---|
| Ricavi | 5,46 Mln | - |
| Utile lordo | -651,38K | - |
| Utile netto | 177,82K | - |
| EBITDA | -570,09K | - |
Dati fondamentali
| Metrica | Valore |
|---|---|
Capitalizzazione di mercato | 6,66 Mln € |
Numero di azioni | 1,57 Mln |
Massimo/minimo a 52 settimane | 22,21 € - 3,59 € |
| Dividendi | No |
Beta | 0,26 |
Rapporto P/E | -17,90 |
Rapporto PEG | -0,18 |
Rapporto P/B | 1,56 |
Rapporto P/S | 0,69 |
Profilo aziendale
| Nome | BASEL MED GROUP LTD. O.N. |
| CEO | Yen Feng Chhoa |
| Dipendenti | 82 |
Scopri gli asset
Gli azionisti di BASEL MED GROUP LTD. O.N. investono anche nei seguenti asset
